Johnson & Johnson
NYSEJNJ cost to borrow surges to 0.678%, up 113% in one week as borrow demand tightens despite low short interest of 1.2% of float.
A new long-form analysis for JNJ this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumJohnson & Johnson has pushed further into recovery territory, adding 6.4% on the week to close at $266.73 — now sitting above several analyst price targets and approaching the upper end of the Street's consensus…
Snapshot as of 6 Aug 2026
Johnson & Johnson is doing something unusual post-earnings: options traders have abandoned their defensive posture at a pace that has driven the put/call ratio to its lowest reading in a full year. The options signal…
Johnson & Johnson has printed its Q2 2026 results and the stock's reaction tells the story clearly: at $253.85, JNJ is now down 5% on the week and sitting roughly $8 below the Street's consensus mean of $262.27 — a…
Johnson & Johnson arrives at its Q2 2026 earnings release trading at $253.85, roughly $8 below the Street's consensus mean price target of $262.27 — the widest discount to analyst estimates this stock has seen in the…
Johnson & Johnson heads into Tuesday's Q2 print having given back a chunk of its recent rally, with the stock now trading below even the updated analyst consensus mean. The price reversal is the sharpest development…
Johnson & Johnson has moved further ahead of consensus this week, with the stock now trading above even the most recently upgraded analyst targets and Q2 earnings just six days away. The Street played catch-up on…
Johnson & Johnson slipped 0.8% on the week to close at $235.18, a modest pullback after the stock's strongest four-week run in over a year — and with Q2 earnings now less than four weeks away, options traders are…
Johnson & Johnson has extended its post-Firefly momentum, adding another 6.3% this week to close at $237 — and the focus is now shifting from the acquisition narrative to what the July 14 earnings print will…
Johnson & Johnson has stabilised at $222.89 this week, but the short-selling story that defined last week's note has taken a twist — shorts are pulling back even as the stock continues to slide. Last week's report…
Johnson & Johnson enters the back half of May with fresh analyst momentum but a stock that has given back 6% over the past month — a tension that sets up an interesting read on where the market is willing to take a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JNJ — free to start on ORTEX.
Sign up for free →Open JNJ on ORTEX